Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis

被引:9
|
作者
Beaver, Thomas [1 ]
Bavaria, Joseph E. [2 ]
Griffith, Bartley [3 ]
Svensson, Lars G. [4 ]
Pibarot, Philippe [5 ]
Borger, Michael A. [5 ]
Sharaf, Omar M. [1 ]
Heimansohn, David A. [6 ]
Thourani, Vinod H. [7 ]
Blackstone, Eugene H.
Puskas, John D. [8 ]
机构
[1] Univ Florida Hlth, Div Cardiovasc Surg, Gainesville, FL USA
[2] Hosp Univ Penn, Dept Cardiovasc Surg, Philadelphia, PA USA
[3] Univ Maryland, Med Ctr, Dept Surg, Baltimore, MD USA
[4] Cleveland Clin, Dept Thorac & Cardiovasc Surg, Cleveland, OH USA
[5] Laval Univ, Quebec Heart & Lung Inst, Dept Cardiol, Quebec City, PQ, Canada
[6] St Vincent Heart Ctr Indiana, Indianapolis, IN USA
[7] Piedmont Heart Inst, Marcus Valve Ctr, Dept Cardiovasc Surg, Atlanta, GA USA
[8] Mt Sinai Morningside, Dept Cardiovasc Surg, New York, NY USA
来源
关键词
aortic valve replacement; aortic valve disease; bioprosthetic valve; RESILIA tissue; PRESERVATION TECHNOLOGY; DEFINITIONS; GUIDELINES; DABIGATRAN; WARFARIN; FAILURE;
D O I
10.1016/j.jtcvs.2023.09.047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: As bioprosthetic aortic valve replacement (AVR) extends to younger cohorts, tissue durability is of paramount importance. We report 7-year outcomes from an AVR bioprosthesis utilizing novel tissue. Methods: This was an international investigational device exemption trial for novel AVR with annual follow-up and a subset re-consented at 5 years for extended 10-year follow-up. Safety end points and echocardiographic measurements were adjudicated by an independent clinical events committee and by a dedicated core laboratory, respectively. Results: Between January 2013 and March 2016, 689 patients underwent AVR with the study valve. Mean age was 66.9 +/- 11.6 years, Society of Thoracic Surgeons risk score was 2.0% % +/- 1.8%, % , and 74.3% % of patients were New York Heart Association functional class II and III. Five-year follow-up was completed by 512 patients, and 225 re-consented for extended follow-up. Follow-up duration was 5.3 +/- 2.2 years (3665.6 patient-years), and 194 and 195 patients completed 6-and 7-year follow-ups, respectively. One-, 5-, and 7-year freedom from all-cause mortality was 97.7%, % , 89.4%, % , and 85.4%, % , respectively. Freedom from structural valve deterioration at 7 years was 99.3%. % . At 7 years, effective orifice fi ce area and mean gradients were 1.82 +/- 0.57 cm(2) (n = 153), and 9.4 +/- 4.5 mm Hg (n = 157), respectively. At 7 years, predominantly none (96.8% % [152 out of 157]) or trivial/trace (2.5% % [4 out of 157]) paravalvular regurgitation and none (84.7% % [133 out of 157]) or trivial/trace (11.5% % [18 out of 157]) transvalvular regurgitation were observed. Conclusions: We report the longest surgical AVR follow-up with novel tissue in an investigational device exemption trial utilizing an independent clinical events committee and an echocardiography core laboratory. This tissue demonstrates excellent outcomes through 7 years and is the benchmark for future surgical and transcatheter prostheses.
引用
收藏
页码:781 / 791
页数:11
相关论文
共 50 条
  • [1] Discussion to: Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis
    Beaver, Thomas
    Preventza, Ourania
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 168 (03): : 792 - 793
  • [2] Final 5-year outcomes following aortic valve replacement with a RESILIA™ tissue bioprosthesis
    Bartus, Krzysztof
    Litwinowicz, Radoslaw
    Bilewska, Agata
    Stapor, Maciej
    Bochenek, Maciej
    Rozanski, Jacek
    Sadowski, Jerzy
    Filip, Grzegorz
    Kusmierczyk, Mariusz
    Kapelak, Boguslaw
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2021, 59 (02) : 434 - 441
  • [3] Five-Year Outcomes After Bicuspid Aortic Valve Replacement With a Novel Tissue Bioprosthesis
    Bavaria, Joseph E.
    Mumtaz, Mubashir A.
    Griffith, Bartley
    Svensson, Lars G.
    Pibarot, Philippe
    Borger, Michael A.
    Thourani, Vinod H.
    Blackstone, Eugene H.
    Puskas, John D.
    ANNALS OF THORACIC SURGERY, 2024, 118 (01):
  • [4] Seven-year outcomes after surgical aortic valve replacement with a stented bovine pericardial bioprosthesis in over 1100 patients: a prospective multicentre analysis
    Sabik III, Joseph F.
    Rao, Vivek
    Dagenais, Francois
    Moront, Michael G.
    Reardon, Michael J.
    Patel, Himanshu J.
    Oh, Jae K.
    Fukuhara, Shinichi
    Labrousse, Louis
    Guenzinger, Ralf
    Baig, Kamran
    Ito, Saki
    Wu, Tianhua
    Klautz, Robert J. M.
    PERIGON Investigators, Gosta
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2025, 67 (01)
  • [5] Intermediate-term outcomes of aortic valve replacement using a bioprosthesis with a novel tissue
    Johnston, Douglas R.
    Griffith, Bartley P.
    Puskas, John D.
    Bavaria, Joseph E.
    Svensson, Lars G.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2021, 162 (05): : 1478 - 1485
  • [6] Savings associated with surgical aortic valve replacement with a RESILIA tissue valve based on seven-year COMMENCE trial results
    Keuffel, Eric L.
    Reifenberger, Matt
    Pellegrini, Andrew
    Nguyen, Tom C.
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 910 - 918
  • [7] Five-year outcomes of surgical aortic valve replacement with a novel bovine pericardial bioprosthesis
    Chen, Jinmiao
    Lv, Minzhi
    Fu, Jiahui
    He, Chen
    Guo, Yingqiang
    Tao, Liang
    Zhou, Xinmin
    Gu, Tianxiang
    Bartus, Krzysztof
    Wei, Lai
    Hong, Tao
    Wang, Chunsheng
    INTERDISCIPLINARY CARDIOVASCULAR AND THORACIC SURGERY, 2024, 38 (01):
  • [8] Intermediate-term outcomes after aortic valve replacement with a novel RESILIA™ tissue bioprosthesis
    Bartus, Krzysztof
    Litwinowicz, Radoslaw
    Bilewska, Agata
    Stapor, Maciej
    Bochenek, Maciej
    Rozanski, Jacek
    Sadowski, Jerzy
    Filip, Grzegorz
    Kapelak, Boguslaw
    Kusmierczyk, Mariusz
    JOURNAL OF THORACIC DISEASE, 2019, 11 (07) : 3039 - 3046
  • [9] Surgical aortic valve replacement with a stented pericardial bioprosthesis: 5-year outcomes
    Klautz, Robert J. M.
    Dagenais, Francois
    Reardon, Michael J.
    Lange, Rudiger
    Moront, Michael G.
    Labrousse, Louis
    Weissman, Neil J.
    Rao, Vivek
    Patel, Himanshu J.
    Liu, Fang
    Sabik, Joseph F., III
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2022, 62 (03)
  • [10] Sutureless bioprosthesis for aortic valve replacement: Surgical and clinical outcomes
    Ferreira, Ricardo
    Rua, Nuno
    Sena, Andre
    Velho, Tiago R.
    Goncalves, Joao
    Junqueira, Nadia
    Almeida, Ana G.
    Nobre, Angelo
    Pinto, Fausto
    JOURNAL OF CARDIAC SURGERY, 2022, 37 (12) : 4774 - 4782